精密医療により遺伝子診断率が向上(Precision medicine helps more patients receive a genetic diagnosis)

ad

2026-03-30 カロリンスカ研究所(KI)

スウェーデンのカロリンスカ研究所の研究によると、精密医療の導入により遺伝性疾患の診断率が向上した。従来の診断では原因不明とされていた患者に対し、全ゲノム解析などの高度な遺伝子検査を適用することで、より多くの患者が遺伝的原因を特定できた。これにより、適切な治療選択や予後予測が可能となり、個別化医療の有効性が示された。また、診断プロセスの効率化や医療資源の最適化にも寄与することが期待される。本研究は、臨床現場における精密医療の実装の重要性を強調している。

<関連情報>

カロリンスカ研究所ゲノム医療センターによる希少疾患のゲノムシーケンスに関する10年間の報告書と段階的な臨床導入戦略 The genomic medicine center Karolinska 10-year report on genome sequencing for rare diseases and a strategy for stepwise clinical implementation

Anna Lindstrand,Kristina Lagerstedt-Robinson,Anders Jemt,Malin Kvarnung,Sofia Ygberg,Sofie Vonlanthen,Mikael Oscarson,Daniel Nilsson,Nicole Lesko,Angelo Salazar Mantero,Britt-Marie Anderlid,Henrik Arnell,Cecilia Arthur,Svetlana Bajalica-Lagercrantz,Michela Barbaro,Peter Bergman,Erik Björck,Oda Blomqvist Picard,Helene Bruhn,Jonas Carlsten,Sandrina P. Correia,Karl De Geer,Angelica M. Delgado Vega,Emma Ehn,… Anna Wedell
Genome Medicine  Published:30 March 2026
DOI:https://doi.org/10.1186/s13073-026-01611-3

精密医療により遺伝子診断率が向上(Precision medicine helps more patients receive a genetic diagnosis)

Abstract

Background

As clinical genetics evolves towards the broader field of clinical genomics, the diagnostic approach to rare diseases is undergoing a paradigm shift. This transformation has significantly impacted rare disease diagnostics, increasingly done through gene panels, whole exome and whole genome sequencing. To advance beyond genomics into precision medicine and encompass the breadth of relevant clinical scenarios, a true systems shift is required that challenges conventional barriers and enables the formation of cross-disciplinary, integrated environments.

Methods

The Genomic Medicine Center Karolinska Rare Diseases (GMCK-RD) has, for the past 10 years, brought together healthcare and academia to enable large-scale genome sequencing in a clinical diagnostics context. Within GMCK-RD, experts from various medical disciplines collaborate closely with clinical geneticists, bioinformaticians, and researchers to integrate genome sequencing into healthcare.

Results

In total, 15 644 individuals with suspected rare diseases were analyzed using clinical genome sequencing, including pediatric (48%), adult (48%) and fetal (4%) samples. The overall diagnostic yield was 22.6%, providing a diagnosis for 3 538 individuals with variants in 1 570 genes. Moreover, a rare disease analysis tool suite developed and validated in house includes a bioinformatic pipeline allowing for comprehensive data analysis covering a wide range of genetic variants including SNVs, INDELs, repeat expansions, uniparental disomies, balanced and unbalanced structural variants as well as insertions of mobile elements. Results are visualized and interpreted in custom-developed decision support systems functioning as an interpretation portal as well as a knowledge-base to capture the interpretation efforts made in a structured format allowing future secondary use.

Conclusions

Altogether, GMCK-RD has shifted healthcare in our region towards precision diagnostics. We emphasize the need to transition from traditional clinical genetic diagnostics to a broader clinical genomics approach. Beyond this shift, we advocate integrating genomics with specialized clinical and laboratory medicine, a concept pioneered for inborn errors of metabolism (IEM) with stepwise spread to additional disease groups. In this model, a multidisciplinary unit combines screening, targeted diagnostics, individualized treatment, and long-term patient follow-up. Here we provide a road map and guide for inspiration for centers aiming to implement genome sequencing in rare disease diagnostics.

医療・健康
ad
ad
Follow
ad
タイトルとURLをコピーしました